About Anelixis

Anelixis Therapeutics was formed in 2013 and is a for-profit subsidiary of ALS Therapy Development Institute (ALSTDI, www.als.net), a nonprofit biotechnology organization dedicated to developing effective treatments for ALS.

Anelixis Therapeutics is a clinical stage development company located in Cambridge, Massachusetts with a portfolio focused on immune modulatory drugs for neurodegenerative diseases with a focus on amyotrophic lateral sclerosis (ALS) and Alzheimer's Disease (AD). Anelixis Therapeutics is committed to advancing treatments that will have a meaningful impact on the lives of patients by helping them battle back their disease progression.

Anelixis Therapeutics' lead molecule, AT-1501, is a monoclonal antibody targeting CD40-ligand that was licensed from ALS TDI. In preclinical studies, it was demonstrated by ALS TDI blocking CD40LG signaling slowed down disease progression, improved survival, and improved muscle function. These landmark studies identified the costimulatory pathway playing a critical role in neurodegeneration. These studies are discussed in greater length here.

Anelixis Therapeutics has assembled an expert clinical advisory team and consulting team. The company has developed a cell line and manufacturing process to develop AT-1501. The team has completed IND enabling toxicology studies in non-human primates and intends to file an IND for first in human studies in early 2018.

Anelixis Therapeutics is led by a management team with more than 20 years of experience driving potential treatments through the life cycle of development at major biotechnology and pharmaceutical companies. The company has received on-going philanthropic support from ALS TDI as well as earned peer-reviewed grants from the ALS Association, ALS Finding a Cure Foundation, ALS ONE and the Congressionally Directed Medical Research Program for ALS operated by the Department of Defense. The Anelixis Therapeutics team has put together the necessary plans to begin clinical trials of AT-1501 in 2018 while seeking additional partnerships to drive the development of AT-1501 and other costimulatory targeting antibodies forward.

Contact us for more information